A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of California, Davis
Neonc Technologies, Inc.
AstraZeneca
Merck Sharp & Dohme LLC
Novartis
NanOlogy, LLC
Astellas Pharma Inc
OHSU Knight Cancer Institute
IDEAYA Biosciences
Incyte Corporation
Sichuan Baili Pharmaceutical Co., Ltd.
Nurix Therapeutics, Inc.
Merck Sharp & Dohme LLC
AbbVie
Toray Industries, Inc
Gilead Sciences
UNICANCER
Shanghai Junshi Bioscience Co., Ltd.
DEKA Biosciences
Sun Yat-sen University
Institute of Cancer Research, United Kingdom
The Netherlands Cancer Institute
GI Innovation, Inc.
Eli Lilly and Company
Actuate Therapeutics Inc.
GlaxoSmithKline
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
Brigham and Women's Hospital
Hoosier Cancer Research Network
Pharmacyclics LLC.
QuantumLeap Healthcare Collaborative
Canadian Cancer Trials Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Nektar Therapeutics
Wake Forest University Health Sciences
Calithera Biosciences, Inc
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
NanOlogy, LLC
Merck Sharp & Dohme LLC
Radiation Therapy Oncology Group
Radiation Therapy Oncology Group